Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
NCT06844357

A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

Led by Zhejiang Raygene Pharmaceuticals Co., Ltd · Updated on 2025-04-06

300

Participants Needed

2

Research Sites

209 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This phase I/II clinical trial aims to determine the efficacy and safety of TATE compared to TACE in patients with intermediate-stage HCC. The results will provide valuable insights into the potential benefits of TATE as a novel treatment option for HCC.

CONDITIONS

Official Title

A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients diagnosed with primary hepatocellular carcinoma according to AASLD criteria
  • No evidence of extrahepatic metastasis, regional lymph node involvement, or vascular tumor thrombus
  • Eligible for Transarterial Embolization (TAE) or Transarterial Chemoembolization (TACE) treatment
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Child-Pugh score of 7 or less
  • Adequate bone marrow, liver, and kidney function
Not Eligible

You will not qualify if you...

  • History of liver transplantation
  • Previous radioembolization or radiotherapy for liver tumors
  • Severe cardiovascular or renal diseases
  • Active systemic infections
  • Clinically significant hypoxia (oxygen saturation below 92% without oxygen supplementation)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Zhongda Hospital, Affiliated to Southeast University

Nanjing, Jiangsu, China, 210009

Actively Recruiting

2

Lishui Central Hospital

Lishui, Zhejiang, China, 323000

Actively Recruiting

Loading map...

Research Team

B

Bill Shen, Ph.D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here